267 related articles for article (PubMed ID: 32124580)
1. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
Rawson NSB
Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
[TBL] [Abstract][Full Text] [Related]
3. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
[TBL] [Abstract][Full Text] [Related]
4. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
Rawson NSB; Stewart DJ
Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
[TBL] [Abstract][Full Text] [Related]
5. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR.
Richter T; Janoudi G; Amegatse W; Nester-Parr S
Orphanet J Rare Dis; 2018 Feb; 13(1):15. PubMed ID: 29386040
[TBL] [Abstract][Full Text] [Related]
7. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
Rawson NS
Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
[TBL] [Abstract][Full Text] [Related]
8. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
McCormick JI; Berescu LD; Tadros N
Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
[TBL] [Abstract][Full Text] [Related]
10. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
Husereau D; Dempster W; Blanchard A; Chambers J
Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
[TBL] [Abstract][Full Text] [Related]
11. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health.
Balijepalli C; Gullapalli L; Joshy J; Rawson NS
J Comp Eff Res; 2024 May; 13(5):e230178. PubMed ID: 38567953
[TBL] [Abstract][Full Text] [Related]
12. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
Binder L; Ghadban M; Sit C; Barnard K
Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
[TBL] [Abstract][Full Text] [Related]
13. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
Menon D; Clark D; Stafinski T
Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
[TBL] [Abstract][Full Text] [Related]
14. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
[TBL] [Abstract][Full Text] [Related]
15. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
Rocchi A; Mills F
J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
[TBL] [Abstract][Full Text] [Related]
16. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
[TBL] [Abstract][Full Text] [Related]
17. Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models.
Glennie J; Villalba E; Wheatley-Price P
Curr Oncol; 2022 Feb; 29(2):981-988. PubMed ID: 35200582
[TBL] [Abstract][Full Text] [Related]
18. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
Wonder M; Chin G
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
[TBL] [Abstract][Full Text] [Related]
19. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
[TBL] [Abstract][Full Text] [Related]
20. Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025.
Lech R; Chow G; Mann K; Mott P; Malmberg C; Forte L
Orphanet J Rare Dis; 2022 Oct; 17(1):371. PubMed ID: 36209128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
